NovoCure
NVCR
317 hedge funds and large institutions have $5.64B invested in NovoCure in 2022 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 91 increasing their positions, 107 reducing their positions, and 43 closing their positions.
30% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 43
3% more funds holding
Funds holding: 309 → 317 (+8)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.98% less ownership
Funds ownership: 78.14% → 77.16% (-0.98%)
15% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 107
17% less capital invested
Capital invested by funds: $6.8B → $5.64B (-$1.16B)
18% less call options, than puts
Call options by funds: $69.3M | Put options by funds: $84.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$137M |
| 2 |
BlackRock
New York
|
+$45.2M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25.7M |
| 4 |
Morgan Stanley
New York
|
+$22.5M |
| 5 |
Jane Street
New York
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$258M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$69.9M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$21.3M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$16.9M |
| 5 |
State Street
Boston,
Massachusetts
|
-$15.8M |
NVCR Hedge Fund Activity: Q2 2022 in Review
317 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2022, worth a combined $5.64B — down 17% from $6.8B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new NVCR positions and 43 closed out — a net gain of 13 holders — while 91 added to existing stakes and 107 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $137M. The largest seller was Capital International Investors, cutting an estimated $258M.
- 317 institutional investors held NovoCure (NVCR) as of Q2 2022, up from 309 in Q1 2022.
- Funds reported $5.64B of NovoCure stock for Q2 2022, down 17% quarter-over-quarter.
- 56 funds opened new NovoCure positions in Q2 2022 and 43 closed out, a net change of +13 holders.
- The largest NovoCure buyer in Q2 2022 was Fidelity Investments, an estimated $137M added.
- The largest NovoCure seller in Q2 2022 was Capital International Investors, an estimated $258M sold.
Based on aggregated 13F filings for Q2 2022.